Recursion Pharmaceuticals (RXRX) News Today $6.53 +0.13 (+2.03%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Avanza Fonder AB Acquires Shares of 85,860 Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Avanza Fonder AB purchased a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 85,860 shares of the company's stock, valued at approximately $January 20 at 3:43 AM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 4.5% - Still a Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 4.5% - Still a Buy?January 17 at 3:05 PM | marketbeat.comIs Recursion Pharmaceuticals Stock a Buy?January 17 at 5:47 AM | fool.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3.6% - Should You Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 3.6% - Should You Sell?January 16, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.5% Higher - Still a Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 0.5% - Time to Buy?January 16, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.8% - What's Next?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.8% - Here's What HappenedJanuary 15, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 4.4% - Here's What HappenedRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 4.4% - Still a Buy?January 15, 2025 | marketbeat.comBank of America Securities Sticks to Its Hold Rating for Recursion Pharmaceuticals (RXRX)January 14, 2025 | markets.businessinsider.comRecursion needs ‘definitive wins’ to validate platform, says JPMorganJanuary 14, 2025 | markets.businessinsider.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.8% - Time to Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 4.8% - Time to Sell?January 13, 2025 | marketbeat.comRecursion Pharmaceuticals: Betting Big On AIJanuary 12, 2025 | seekingalpha.comRecursion Pharmaceuticals (NASDAQ:RXRX) Price Target Lowered to $10.00 at KeyCorpJanuary 11, 2025 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.3% - Time to Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 4.3% - What's Next?January 10, 2025 | marketbeat.comRecursion: Investors Will Need To Be PatientJanuary 10, 2025 | seekingalpha.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 3.1% on Analyst DowngradeJanuary 10, 2025 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3.1% Following Analyst DowngradeRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 3.1% Following Analyst DowngradeJanuary 9, 2025 | marketbeat.comCathie Wood’s ARK Investment buys 653K shares of Recursion Pharmaceuticals todayJanuary 9, 2025 | markets.businessinsider.comRecursion Pharmaceuticals price target lowered to $10 from $12 at KeyBancJanuary 8, 2025 | markets.businessinsider.comRecursion Pharmaceuticals (NASDAQ:RXRX) Price Target Cut to $10.00 by Analysts at KeyCorpKeyCorp reduced their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research report on Wednesday.January 8, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.4% - Time to Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.4% - What's Next?January 8, 2025 | marketbeat.comRecursion announces two oncology drugs advancing to clinical trialsJanuary 7, 2025 | markets.businessinsider.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 2.4% - Should You Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 2.4% - Should You Sell?January 7, 2025 | marketbeat.comRecursion Pharmaceuticals price target lowered to $10 from $12 at BofAJanuary 7, 2025 | markets.businessinsider.comStock Traders Buy High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Investors acquired 15,360 call options on the stock. This is an increase of 44% compared to the average volume of 10,636 call options.January 7, 2025 | marketbeat.comRecursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & MoreJanuary 7, 2025 | globenewswire.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.9% - Time to Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.9% - What's Next?January 6, 2025 | marketbeat.comRecursion to Present at 43rd Annual JP Morgan Healthcare ConferenceJanuary 6, 2025 | globenewswire.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 5.3% Higher - Here's What HappenedRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 5.3% Higher - Time to Buy?January 3, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 8.1% - Still a Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 8.1% - Should You Buy?January 2, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 0.1% - Should You Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 0.1% - Here's What HappenedJanuary 1, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 3.7% - Here's What HappenedRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 3.7% Higher - Time to Buy?December 31, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 7.6% - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 7.6% - Here's What HappenedDecember 30, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.6% - Should You Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.6% - Here's WhyDecember 27, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 1.9% - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 1.9% - Here's What HappenedDecember 26, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down - Time to Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down - Time to Sell?December 26, 2024 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Bought by Geode Capital Management LLCGeode Capital Management LLC grew its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,431,911 shares ofDecember 26, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 3.6% Higher - Still a Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 3.6% - What's Next?December 25, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 1% - Should You Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 1% - Here's WhyDecember 24, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Sees Unusually-High Trading Volume - What's Next?Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Strong Trading Volume - Here's WhyDecember 24, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 5.5% - Here's What HappenedRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 5.5% Higher - Still a Buy?December 23, 2024 | marketbeat.comTraders Buy High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) saw some unusual options trading on Monday. Traders acquired 13,040 call options on the company. This is an increase of approximately 42% compared to the typical volume of 9,161 call options.December 23, 2024 | marketbeat.comBarclays PLC Purchases 244,278 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Barclays PLC boosted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 53.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 697,432 shares of the company's stock afterDecember 22, 2024 | marketbeat.comIs Recursion Pharmaceuticals Stock a Millionaire Maker?December 21, 2024 | fool.com1 Artificial Intelligence (AI) Stock That Could Soar in 2025December 21, 2024 | fool.com105,018 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Bought by Wellington Management Group LLPWellington Management Group LLP bought a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 105,018 shares of the company's stock, vDecember 21, 2024 | marketbeat.comRecursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesDecember 20, 2024 | globenewswire.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 0.7% - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 0.7% - Time to Buy?December 20, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.6% Higher - What's Next?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.6% Higher - Here's What HappenedDecember 19, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - What's Next?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - What's Next?December 19, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 3.4% - Time to Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 3.4% - Time to Sell?December 18, 2024 | marketbeat.com Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address RXRX Media Mentions By Week RXRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RXRX News Sentiment▼0.280.44▲Average Medical News Sentiment RXRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RXRX Articles This Week▼98▲RXRX Articles Average Week Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Roivant Sciences News Today Ascendis Pharma A/S News Today Blueprint Medicines News Today Revolution Medicines News Today BridgeBio Pharma News Today Lantheus News Today Legend Biotech News Today Elanco Animal Health News Today Cytokinetics News Today Nuvalent News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RXRX) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
